6108 (6108) Fair Value & Analysis

Healthcare · Market cap HK$41.3M

6 6108 6108 · HK

PriceHK$0.2060

Fair ValueHK$0.1282

Upside-37.8%

Quality48/100

Watch 6108 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$0.0846 – HK$0.1603

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price +1.5% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.1990 – HK$0.4700 · fair‑value band HK$0.0846 – HK$0.1603 · the HK$0.2060 price screens above the HK$0.1282 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6108 (6108) currently trades at HK$0.2060, while our model-based Fair Value estimate is HK$0.1282 — implying the stock looks roughly 37.8% overvalued today. We read business quality at 48/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 6108 generated revenue of HK$130M at a net margin of -15.4%. Revenue grew 10.9% year over year. It earns a return on equity of -4.5%. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$130M

Revenue growth (YoY) +10.9%

Net margin -15.4%

Return on equity -4.5%

Free cash flow −HK$54.5M FY2025

Operating margin -10.5%

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6108 reported revenue of HK$130M in FY2025 versus HK$335M in FY2021, a compound −21.0%/yr. Reported net income was −HK$20.1M in FY2025.

Revenue −21.0%/yr

FY21 HK$335M

FY22 HK$89.8M

FY23 HK$50.2M

FY24 HK$93.9M

FY25 HK$130M

Net income

FY21 −HK$2.8M

FY22 −HK$77.9M

FY23 −HK$22.2M

FY24 −HK$31.0M

FY25 −HK$20.1M

Is 6108 fairly valued? → Check now

Similar stocks

6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
JD Health International Inc JDHIY	$5.33	$7.09	+33%
6618 6618	HK$34.16	HK$33.08	-3%
Alibaba Health Information Technology Limited ALBBY	$8.56	$6.91	-19%
0241 0241	HK$3.08	HK$2.04	-34%
Raia Drogasil S.A RADL3	R$17.46	R$16.13	-8%
Yifeng Pharmacy Chain Co 603939	¥20.91	¥22.00	+5%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6108 (6108) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.1282 versus a price of HK$0.2060 — about −38% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 6108?

Our model-based fair value for 6108 is HK$0.1282 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.2060.

What is the quality score of 6108?

6108 has a Quality Score of 48/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6108 (6108)?

6108 reported trailing-twelve-month revenue of about HK$130M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6108?

The net profit margin of 6108 is about -15.4%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.